Leadership

Joel Ackerman, Chief Executive Officer

Joel Ackerman spent 15 years at Warburg Pincus, a leading private equity investment firm, from 1993 to 2008. While at Warburg Pincus, he was a partner of the firm, a member of the executive management group and ran the healthcare services group. He invested in start-ups and early-stage companies as well as later-stage growth investments and management-led buyouts. For most of these companies, Mr. Ackerman served on the board of directors and worked closely with the respective management teams on strategy, financing, M&A and organizational development. Currently, Mr. Ackerman sits on the board of directors of Coventry Health Care, a publicly traded managed care company, and Kindred Healthcare, a publicly traded company that owns hospitals and nursing homes. He is also chairman of the board of One Acre Fund, a nonprofit microfinance organization in Western Kenya. He received a BA in physics from Columbia University and an MA in physics from Harvard University.


Ronnie Morris, MD, President

Ronnie Morris, MD, was most recently one of the founders of MDVIP, the national leader in personalized healthcare. Serving as a board member, medical director and part of the executive management team, Dr. Morris helped build and manage MDVIP, a company that grew to a network of 400 doctors within 29 states servicing 125,000 consumers/patients. In December 2009, MDVIP was acquired by the Procter and Gamble Co. Prior to MDVIP, Dr. Morris was the chief medical officer and executive VP of AllianceCare, a 1500-plus-employee company that provided home healthcare, physical therapy and doctor visits for homebound patients. At AllianceCare, Dr. Morris developed and operated the physician house call division of the business, and he was the general medical director for the company. He was the managing partner of a large multispecialty group that was acquired in 1998 by ProMedCo. Dr. Morris is a board-certified internist and until 2004, he had a private practice in Boca Raton, Florida. He has been a consultant for many pharmaceutical companies, including Pfizer, Merck and AstraZeneca.


Angela M. Davies, MD, FRCP (C), Chief Medical Officer

Angela M. Davies, MD, FRCP(C) joined Champions Oncology in January 2014 as the company’s chief medical officer. Most recently, Dr. Davies served as chief medical officer at Novocure, where she had global responsibility for the organization’s clinical development program and commercial safety. Dr. Davies previously served as chief medical officer at OSI Pharmaceuticals where she led the oncology clinical development program for Tarceva (erlotinib) and the pipeline compounds. Prior to OSI she was associate professor of medicine at University of California, Davis where she practiced as a medical oncologist specializing in thoracic malignancies and development therapeutics. Dr. Davies is a board-certified internist and medical oncologist. She obtained her medical degree and completed her specialty medical training at McMaster University, Hamilton, Canada and University of Toronto, Toronto, Canada.


Jordan Rubinson, MBA, Vice President, Sales & Marketing

Jordan Rubinson has 17 years’ experience in the pharmaceutical industry with Pfizer, GlaxoSmithKline, Aventis and most recently as the CEO of Polyheal Ltd., which is strategically allied with Teva Pharmaceuticals. Immediately prior, Mr. Rubinson worked at Pfizer as the marketing director in Israel, where he launched five new products in three years. Just prior at GSK, Mr. Rubinson worked in U.S. marketing where he managed assets of over $200M in annual sales, brought to market several category-leading vaccines, and earned the company Frost and Sullivan’s Market Engineering Excellence Award. He also worked in GSK France managing a large field force division of over 100 employees. While at Aventis, Mr. Rubinson had assignments in France, Canada and the U.S. in the areas of strategic marketing, manufacturing and sales. Mr. Rubinson holds an engineering degree from Columbia University and an MBA from MIT’s Sloan School of Management.


Keren Paz, PhD, Vice President, Scientific Innovation

Keren Paz, PhD, was named the vice president, scientific innovation for personalized oncology services in June 2011. Dr. Paz holds a bachelor of science degree from Tel Aviv University, a master of science degree in biochemistry and a PhD in molecular biology and biochemistry from the Weizmann Institute of Science in Israel. She completed EMBO-awarded and Human Frontiers-awarded postdoctoral fellowships at Memorial Sloan-Kettering Cancer Center and at Rockefeller University in New York City. Dr. Paz’s academic training focused on research in the field of signal transduction, molecular and cellular biology and bioinformatics.

In 2003, Dr. Paz joined ImClone Systems, overseeing a number of drug discovery programs in the oncology field, from the early preclinical stage through Investigational New Drug applications to late-stage clinical development. She also supervised the bioinformatics and biomarker program at the company, supporting the entire ImClone pipeline. Most recently, Dr. Paz led the Translational Sciences and Patient Tailoring group at ImClone. In this position, she also served as the ImClone representative and an active member of the Global Oncology Patient Tailoring team at the Eli Lilly Oncology Business Unit.


Jim McGorry, MBA, Executive Vice President and General Manager, Translational Oncology Solutions

Jim McGorry is a dynamic life sciences leader with a proven track record from over 25 years of strategic and operational leadership. Jim has a wide range of experience across multiple therapeutic areas and numerous global product launches.

Jim spent 12 years at Genzyme Corporation as a senior vice president in the Biosurgery and Oncology business units, with responsibilities in general management and commercial operations. Jim’s expertise is in commercial effectiveness and operational execution. Prior to Genzyme, Jim spent 11 years at Baxter Healthcare in a wide range of advancing leadership positions. Jim also sits on the board of Harvard Apparatus Regenerative Technology. Jim received a BS in engineering from the United States Military Academy at West Point and a MBA from the Fuqua School of Business at Duke University.


Neal Goodwin, PhD, Vice President, Corporate Research Development

Neil Goodwin, PhD, serves as vice president, corporate research development for Champions Oncology. His responsibilities include development of the patient-derived TumorGraft pharmacology portfolio for both the Personalized Oncology and Translational Oncology Solutions. He previously served as the director, research and development, and the founding program director of JAX Cancer Services. Dr. Goodwin was the cofounder and chief scientific officer of ProNAi Therapeutics, an advanced clinical trial-staged oncology therapeutics firm. He also previously served as a senior research scientist in genomic technologies at Pharmacia. Dr. Goodwin received a PhD in microbiology from the University of Montana and served a postdoctoral fellowship in functional genomics at The Jackson Laboratory with John Schimenti (now at Cornell).


David Miller, MBA, Vice President, Finance

David Miller serves as the vice president of finance at Champions Oncology, Inc. Mr. Miller served as vice president of finance and Operations at DMCWW, LLC. From January 2006 to March 2010, he served as the chief financial officer of NAF Funding, LLC. From January 2000 to December 2005, he served as vice president of finance and Operations at IDT Corp., where he led the creation and growth of the consumer phone services division to over one million customers of local and long distance service. From 1997 to 1999, he served as an assistant vice president of the internal audit department at Deutche Bank. He also held senior accountant positions at Schonbraun, Safris, Sternlieb, LLC and Margolin, Winer and Evans. He is a Certified Public Accountant. He holds a B.S. from Yeshiva University in 1991 and an MBA from Fordham in 1999.




Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology